About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
PIRS - Pieris Pharmaceutica...| Previous Close | $3.45 | Open | $3.43 |
| Volume | 2.58M | Market Cap | 218.4M |
| Yield | Last Dividend |
| Do Analysts Think You Should Buy: Vaxart... | 07/19/21 |
| Vaxart, Inc. (VXRT) with the stream of 9.22% also noticed, India Pieris Pharmaceuticals, Inc. (PIRS) encountered a rapid change of 4.78% in the last h... | |
| Stock Mover: Ashford Hospitality Trust, ... | 07/12/21 |
| Ashford Hospitality Trust, Inc. (AHT) with the stream of 1.51% also noticed, India Pieris Pharmaceuticals, Inc. (PIRS) encountered a rapid change of -... | |
| ITM Appoints Dr. Sabine Daugelat as Chie... | 07/06/21 |
| GARCHING & MUNICH, Germany--(BUSINESS WIRE)--ITM AG, a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Sabine Daug... | |
| This Risky Micro-Cap Could Pay Off Big | 06/30/21 |
| Pieris Pharmaceuticals is introducing a whole new class of drugs to the marketplace. | |
| Pieris Pharmaceuticals Shares Rise 19% A... | 06/29/21 |
| Pieris Pharmaceuticals Shares Rise 19% After Getting Orphan Drug Status MarketWatch | |
| Pieris Pharma stock soars 17% on develop... | 06/25/21 |
| No summary available. | |
| Pieris Pharmaceuticals, Inc.: Pieris Pha... | 06/25/21 |
| PRS-220, an oral inhaled Anticalin protein targeting CTGF, a fully proprietary drug candidate for respiratory disease, is being developed as a local t... | |
| What Makes Penny Stock Pieris Pharma A S... | 06/25/21 |
| No summary available. | |
| The Buzz Show: Pieris Pharmaceuticals, I... | 06/24/21 |
| FinancialBuzz.coms latest The Buzz Show: Featuring Our Corporate News Recap on Pieris Pharmaceuticals, Inc. Receives Orphan Drug Designation for Cinre... | |
| 3 Top Stocks Under $10 | 06/24/21 |
| Are you looking for cheap stocks with a lot of upside? Check out Rolls-Royce, Pieris Pharmaceuticals, and Kahoot! | |
| Pieris Pharmaceuticals shares rise after... | 06/24/21 |
| No summary available. | |
| Pieris Pharmaceuticals, Inc.: Pieris Pha... | 06/24/21 |
| BOSTON, MA / ACCESSWIRE / June 24, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherap... | |
| Traders cant brush off this: Pieris Phar... | 06/14/21 |
| Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) with the stream of 1.58% also noticed, India AIM ImmunoTech Inc. (AMEX:AIM) encountered a rapid change of 4... | |
| Investors Alert (Volume Pattern in Focus... | 06/10/21 |
| On Thursday, Shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) reached at $3.58 price level during last trade its distance from 20 days simple movi... | |
| Flashy Stock: Pieris Pharmaceuticals, In... | 06/09/21 |
| Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) with the stream of 10.19% also noticed, India SunLink Health Systems, Inc. (AMEX:SSY) encountered a rapid c... | |
| Pieris Pharmaceuticals Inc Shares Close ... | 05/28/21 |
| Pieris Pharmaceuticals Inc (PIRS) shares closed this week 78.2% higher than it did at the end of last week. The stock is currently up 37.6% year-to-d... | |
| Where Will The Pieris Pharmacuetical Sto... | 05/26/21 |
| Shares of Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS ) on Full story available on Benzinga.com | |
| Pieris and Genentech to develop respirat... | 05/26/21 |
| Biotechnology company Pieris Pharmaceuticals has signed a multi-programme research collaboration and licence agreement with Roche Group subsidiary Gen... | |
| LRMR Hit By ''double Whammy'', PRVB On W... | 05/26/21 |
| SOUTH SAN FRANCISCO (dpa-AFX) - Today''s Daily Dose brings you news about the clinical hold imposed by the FDA on Larimar''s CTI-1601 clinical program... | |
| Genentech taps small Boston pharma in $2... | 05/25/21 |
| Pieris Pharmaceuticals, a small biotech behind a suite of engineered proteins it calls anticalins, has signed a major research and development deal wi... | |
| The Buzz Show: Pieris Pharmaceuticals (N... | 05/25/21 |
| FinancialBuzz.coms latest The Buzz Show: Featuring Our Corporate News Recap on Pieris Pharmaceuticals, Inc. Climbs Following Respiratory and Ophthalmo... | |
| Genentech taps small Boston pharma for $... | 05/25/21 |
| Pieris Pharmaceuticals, a small biotech behind a suite of engineered proteins it calls anticalins, has signed a major research and development deal wi... | |
| Pieris Stock Surges on Development Pact ... | 05/25/21 |
| Pieris Pharmaceuticals Inc (NASDAQ: PIRS ) has entered into a multi-program research collaboration and license agreement with Genentech , a unit of Ro... | |
| Pieris Pharma nabs $20M upfront from Roc... | 05/25/21 |
| Pieris Pharma nabs $20M upfront from Roche''s Genentech for respiratory, ophthalmology pact klahucik Tue, 05/25/2021 - 10:27 | |
| Pieris Pharma Soars on Alliance With Roc... | 05/25/21 |
| No summary available. | |
| Pieris Pharma jumps on collaboration wit... | 05/25/21 |
| No summary available. | |
| Pieris Pharmaceuticals (PIRS) Stock Clim... | 05/25/21 |
| PIRS stock is screaming for the top in the market this morning after the company announced a collaboration with Genentech. | |
| Pieris Pharmaceuticals Announces Respira... | 05/24/21 |
| Pieris will receive $20 million as an upfront payment and is eligible to receive more than $1.4 billion in additional potential milestone payments plu... | |
| Pieris Pharmaceuticals, Inc. to Host Ear... | 05/20/21 |
| Pieris Pharmaceuticals, Inc. to Host Earnings Call Yahoo Finance | |
| Pieris Pharmaceuticals, Inc.: Pieris Pha... | 05/20/21 |
| BOSTON, MA / ACCESSWIRE / May 20, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherape... | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Trading Systems | Trading Systems | 83.00 % | Follow |
| Mojo Day Trading | ProTrader Mike | 46.00 % | Subscribe |
| Option Ripper | Option Ripper | 34.00 % | Follow |
| cerevisiology | John Cho | 19.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
